Skip to main content

Heart Failure clinical trials at UCSF
18 studies in progress, 8 open to new patients

  • Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure

    open to eligible people ages 21 years and up

    The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).

    Fresno, California and other locations

  • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

    open to eligible people ages 18 years and up

    The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

    Fresno, California and other locations

  • INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

    open to eligible people ages 18 years and up

    INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.

    San Francisco, California and other locations

  • Mechanical Support Measures of Adjustment and QOL

    open to eligible people ages 19 years and up

    The purpose of this study is to develop a measurement system to assess adjustment to mechanical circulatory support (MCS) (also referred to as a ventricular assist device [VAD]) and health-related quality of life (HRQOL) in patients with advanced heart failure who receive a VAD. This investigators refer to this measurement system as Mechanical Circulatory Support: Adjustment and Quality of Life (MCS A-QOL).

    San Francisco, California and other locations

  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    open to all eligible people

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    San Francisco, California and other locations

  • Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF..

    San Francisco, California and other locations

  • Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)

    open to eligible people ages 18 years and up

    The purpose of this study is to determine whether using a mobile app increases adherence to a heart healthy prescription after discharge from a cardiac rehab program.

    Walnut Creek, California and other locations

  • The Product Surveillance Registry REVERSE Post Approval Study

    open to all eligible people

    The purpose of the REVERSE Post Approval Study (PAS) is to confirm the benefit observed in the REVERSE and RAFT pivotal studies in "real-world" clinical practice.

    San Francisco, California and other locations

  • Dynamic Heart Failure Prediction With Real-time Functional Status Data in the Ambulatory Setting

    Sorry, not yet accepting patients

    Heart failure is the number one cause of hospital readmission in those over 65 years of age and the current standard-of-care of weight self-monitoring is inadequate to predict exacerbation. This project aims to improve the monitoring of heart failure disease progression through the use of real-time, up-to-date data obtained both from a smart phone-based tool and from the electronic health record. The goal is to develop a low-risk, clinically validated method to estimate dynamic heart failure risk to enable the provision of earlier, more effective outpatient interventions that decrease hospitalization.

    San Francisco, California

  • Home Outpatient Monitoring and Engagement to Predict HF Exacerbation

    Sorry, not yet accepting patients

    The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health. This study uses the Eureka app, a new study app developed by the University of California, San Francisco. The study is designed to happen remotely, using this application on a patient's smartphone, so that is as convenient as possible to participate.

  • Remote Dielectric Sensing Technology Guided Diuresis in Hospitalized Patients With Acute Decompensated Heart Failure

    Sorry, not yet accepting patients

    This study evaluates the use of a wearable vest capable of non-invasively measuring lung fluid content in hospitalized patients with heart failure

  • Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Global Non-interventional Heart Failure Disease Registry

    Sorry, in progress, not accepting new patients

    The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

    San Francisco, California and other locations

  • HW006 LATERAL Thoracotomy

    Sorry, in progress, not accepting new patients

    This is a prospective, multi-center,single-arm study that will evaluate the thoracotomy implant technique in up to 145 subjects implanted via thoracotomy with the HeartWare HVAD System and enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs®) protocol and database. All participating centers are current INTERMACS® sites in good standing and follow the INTERMACS® protocol and procedures.

    San Francisco, California and other locations

  • Model 4296 Left Ventricular (LV) Lead Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Model 4396 Left Ventricular (LV) Lead Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

    Sorry, in progress, not accepting new patients

    This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

    San Francisco, California and other locations

  • Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether multiple gated acquisition (MUGA) guided lead placement improves clinical outcomes for patients needing cardiac resynchronization therapy (CRT) compared to traditional posterolateral left ventricular lead placement.

    San Francisco, California